Although CDK4/6i has been clinically approved for breast cancer treatment [22], CDK4/6i monotherapy did not induce cytotoxicity in HL60 cells, as evidenced by the maintenance of their immature state (Fig. 3a) and their rapid re-entry into the cell cycle after the drug was removed (Fig. 3b). Here, CDK4 is linked to breast carcinoma.